Lou Kennedy

  • sam patrick posted an article
    $215.8 million investment will create 380 new jobs in Lexington County, SC see more

     Nephron Pharmaceuticals Corporation (Nephron), a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing, today announced plans to expand operations in Lexington County. The company's $215.8 million investment will create 380 new jobs.
     
    A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products, including those used to treat severe respiratory distress symptoms associated with COVID-19. 
     
    The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. Nephron fills the needs of patients and health care professionals as they arise nationwide, and recently opened a CLIA-certified diagnostics lab.
     
    Headquartered at 4500 12th Street in West Columbia, Nephron’s expansion will add new offices, a new warehouse and production space at its campus in Saxe-Gotha Industrial Park.
     
    The expansion is expected to be completed by Q1 of 2021. Individuals interested in joining the Nephron team should visit https://www.nephronpharm.com/careers

    The Coordinating Council for Economic Development has approved job development credits related to this project.
     
    QUOTES
     
    “The Nephron family is extraordinarily grateful for the opportunity to grow in South Carolina. Thanks to our partnerships with state and local officials, and the trust they have placed in us, we have been able to provide life-saving medications to patients around the world and establish ourselves as the global leader in what we do. We are proud of these achievements and more, and we know our best days are ahead of us. That is what makes this latest announcement so special.” -Nephron Owner & CEO Lou Kennedy
     
    “We are proud to have Nephron Pharmaceuticals in South Carolina. Since coming here they have become an integral part of the community, and recently have been vital in the fight against COVID-19. This new investment of more than $215 million creating 380 new jobs in Lexington County is a great win for Team South Carolina.” -Gov. Henry McMaster
     
    “Nephron is a longtime steward of South Carolina’s business community, and we congratulate them on their continued growth within our state. Today’s announcement is yet another big win for South Carolina, our people and our burgeoning life sciences sector.”  -Secretary of Commerce Bobby Hitt
     
    “We are excited to continue to partner with such an innovative and forward-thinking company like Nephron Pharmaceuticals. We know that Lexington County is a great place to establish and grow a business, and Nephron’s continued success is a testament to good government-business relations.” -Lexington County Council Chairman Scott Whetstone
     
    FIVE FAST FACTS

    •    Nephron Pharmaceuticals Corporation (Nephron) is expanding operations in Lexington County.
    •    The $215.8 million investment is projected to create 380 new jobs.
    •    Nephron is a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing.
    •    Headquartered at 4500 12th Street in West Columbia, S.C.
    •    Individuals interested in joining the Nephron team should visit https://www.nephronpharm.com/careers.

  • sam patrick posted an article
    Partnership Reduces Barriers to Testing, Provides Top Quality to Customers see more

    Compliments of MidlandsBiz

    Partnership Reduces Barriers to Testing, Provides Top Quality to Customers

    Nephron Pharmaceuticals Corporation, one of the fastest-growing pharmaceuticals companies in the country, announced a new collaboration with Methapharm.

    As a part of this collaboration, Nephron will produce kits of methacholine chloride sterile inhalation solution in ready-to-administer concentrations for bronchoprovocation challenge testing, when diagnosing respiratory illnesses, such as asthma.

    “Methapharm will be a fantastic partner,” said Nephron CEO Lou Kennedy. “Patients deserve access to the very best respiratory tests available, that’s what this collaboration will offer, and that’s why we are looking forward to working with Methapharm.”

    Working together with Methapharm, Nephron will be able to supply stable room temperature solution kits, ensuring that testing facilities can continue to rely on the quality and reliability of Provocholine for their bronchoprovocation testing needs.

    “Through this partnership with Nephron, Methapharm continues its mission to help reduce barriers to testing, provide the level of quality our customers expect, and contribute to better healthcare outcomes for our patients,” said Craig Baxter CEO of Methapharm. “We’ve been impressed by Nephron’s capabilities and professionalism.”

    Provocholine® is the only FDA-approved methacholine chloride powder for use in humans. Methapharm, the manufacturer of Provocholine, has always tried to be responsive to needs of our testing partners. For example, in response to the revised ERS technical standard, Methapharm initiated a comprehensive nebulizer characterization study to support the recommendation of PD20 as a clinical endpoint. This was published in a technical bulletin earlier this year.

     

    Nephron

    A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products, including those used to treat severe respiratory distress symptoms associated with COVID-19. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. Nephron fills the needs of patients and health care professionals as they arise nationwide, and recently opened a CLIA-certified diagnostics lab.

  • sam patrick posted an article
    Lindsay Cobbs named to head KPIC at USC see more

    Compliments of Midlands Biz

    The Kennedy Pharmacy Innovation Center (KPIC) announced that James Lindsay Cobbs has been named chair for the center.

    In his role, Cobbs will focus on creating a regulatory affairs program for students in the College of Pharmacy, including classroom, cocurricular, experiential, and post-graduate opportunities, as well as supporting Nephron Pharmaceuticals in regulatory affairs.

    “My priorities will hone in on developing experiential training opportunities that will enable our students to build skills for both traditional and nontraditional pharmacy roles, developing key partnerships that can support training for our students and to identify ways that will make the College of Pharmacy stand light years apart from other colleges across the country,” says Cobbs.

    Cobbs brings a wide array of career experiences to KPIC, ranging from clinical pharmacy to global policy development in the pharmaceutical industry. After graduating from the UofSC College of Pharmacy in 1992, he launched his career as a staff pharmacist at Johns Hopkins Medical Center. After four years, he entered public service as a regulatory affairs professional at the U.S. Food and Drug Administration (FDA) where he served as regulatory project manager, special assistant and lead project manager in the Office of Compliance and later as associate director for regulatory affairs (ADRA) in the Office of Translational Sciences.

    Cobbs then transitioned to the corporate sector at Janssen Pharmaceuticals, a division of Johnson & Johnson as a policy lead in the Americas, Global Regulatory and Policy Intelligence Department. Cobbs later became the head of US Policy, Global Regulatory Policy and Intelligence for UCB (Union Chimique Belge translated as Union Chemical of Belgium), a multinational biopharmaceutical company headquartered in Brussels, Belgium.

    Cobbs says his various roles have led him to this next challenge. “My experience as a pharmacist at a major teaching institution, working as a public health servant, co-leading drug review teams for novel drug products, and regulatory policy and intelligence in the pharmaceutical industry have prepared me for this unique role,” he says.

    Patti Fabel, Pharm.D. and executive director of KPIC is looking forward to joining efforts with Cobbs. “Our faculty, staff, and students can learn a great deal from him due to his background, experience and skill set,” Fabel says. “He will broaden the scope of what KPIC can offer our students and alumni by developing a regulatory affairs program. I’m excited to see the impact he has on the center and college.”

    Dean Stephen J. Cutler says Cobbs is an exceedingly accomplished expert in pharmaceutical regulatory affairs. “His addition to our faculty will bring added depth and breadth to our educational program as we launch our college’s latest initiative, the Regulatory Affairs Academic Program,” Cutler adds. “This academic program will offer regulatory education to our pharmacy students, provide postgraduate education for residents and fellows, and give another educational track to our graduate program. Our partnership with Nephron Pharmaceuticals will afford us a working laboratory for the development of future pharmacists and scientists serving in regulatory affairs. We are thrilled that Lindsay Cobbs will shepherd this initiative for the College of Pharmacy.”

    Cobbs will begin his role on July 1, 2020.

  • sam patrick posted an article
    SC's Post-COVID Future to be discussed June 23 in free webinar see more

    Four leaders from the Palmetto State will be joined by a national expert on Infectious Disease June 23 at 10 a.m. for a free webinar discussion on leadership strategies to help South Carolina weather the challenges of COVID-19 and rebound rapidly from the health, social and economic impacts of the pandemic.

    Entitled “Bold Leadership in the Eye of the Storm: Insights & Strategies to Secure Our Future", the program will feature U.S. Senator Lindsey Graham; University of South Carolina President Robert Caslen; Lou Kennedy, CEO of Nephron Pharmaceuticals; and Dr. Phyllis Arthur, VP Infectious Diseases and Diagnostics Policy, BIO.  The group discussion will be moderated by Sam Konduros, CEO of SCBIO, the state’s life sciences economic development organization.

    The group will discuss such topics as:

    • How major universities, colleges and school systems will strive to safely reopen to welcome back students in the Fall, while also encouraging participation in related educational and social activities that are core to the educational experience
    • National/global feedback on how the life sciences industry has fared to date in the ongoing battle against COVID-19 and other infectious diseases, and the likelihood and timing for major advances in testing, treatment and vaccines becoming available across the country
    • Industry’s perspective on the approach taken to accelerate the reopening of South Carolina’s economy, and what must be done to ensure safety for citizens while battling against the troublesome economic downturn the pandemic has created
    • The strategic importance of developing policy around the re-shoring production of essential healthcare equipment, pharmaceuticals and ingredients, personal protective equipment and other medical products and devices back to the US and South Carolina from abroad.

    Participation in the webinar is free to all interested parties.  Those wishing to participate can register while space remains at https://www.scbio.org/events/lessons-learned-by-industry-government-higher-education-from-the-covid-crisis.   

    The 60-minute program will provide attendees with a real-time review of the pandemic’s impact in South Carolina to date, implications for returning to normalcy in the upcoming months, and insights and strategies to secure and enhance the state’s future.  The panelists will also address a realistic path forward as South Carolina begins the move to return to normalcy while still navigating a virus with no clear endpoint.

    “Our goal is to bring the diverse viewpoints of top leaders in government, industry, education and the life sciences industry together in one forum to assess where we are, and how we can make a difference for our citizens in recovering from COVID-19’s impact in the weeks to come,” said SCBIO CEO Sam Konduros.

    “The panelists will also share their insights on important lessons learned, strategies for the future, and ways for all South Carolinians to come together to solve health, social and economic challenges and improve quality of life for our citizens,” he added.

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 600 firms directly involved and 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.  As the official state affiliate of BIO, PhRMA and AdvaMed, SCBIO members include hundreds of academic institutions, biotech companies, medtech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups.

    For additional information on SCBIO, visit www.SCBIO.org.

     

  • sam patrick posted an article
    Nephron steps up to support USC's planned reopening with donations of sanitizer see more

    Courtesy of Columbia Regional Business Report

    Nephron Pharmaceuticals Corp. is donating more than 100,000 bottles of company-manufactured hand sanitizer to the University of South Carolina as part of the West Columbia-based company's ongoing efforts to help fight COVID-19.

    The first 5,000 bottles arrived on campus today, hand-delivered by Nephron president and CEO Lou Kennedy and Nephron's new van bearing its clinical lab logo to a group of student leaders on the university’s Horseshoe.

    “No matter how tall the challenge is, Gamecocks step up,” Kennedy, a 1984 USC graduate, said in a news release. “Our company is proud to do our part to help the university make sure it is ready to welcome students, staff and faculty back to campus.”

    USC, which closed its campuses in March in response to the COVID-19 pandemic, is resuming in-person instruction in mid-August.

    “We’re grateful to Lou and Bill Kennedy and the entire team at Nephron Pharmaceuticals for this generous gift,” Bob Caslen, USC president, said. “This donation helps support the safe return of our students and employees to campus and exemplifies what the Gamecock spirit is all about: making our communities better through selfless service and caring for others.”

    The bottles bear a private label requested by the university, Kennedy said.

    Nephron develops and produces generic respiratory medication, including inhalation solutions and suspension products that can be used to treat severe respiratory symptoms associated with COVID-19.  

    In March, Nephron began making its own hand sanitizer, and previously donated 50 liters to the William Jennings Bryan Dorn Veteran Affairs Medical Center. The company added a production line in April be used in the manufacturing of bronchodilator albuterol as demand for its products soars during the pandemic.

    Last month, the company announced an expansion of its COVID-19 testing capabilities through a partnership with medical technology company One Medical. Kennedy told the Columbia Regional Business Report today that Nephron’s on-site clinical lab began testing company employees last week and plans to process samples collected during a drive-thru testing clinic June 19 and 20 at Benedict College’s football stadium.

    “We are trying to be a good partner with DHEC, a good partner with the local hospitals, and see how we can take some of the stress off of their labs for testing,” said Kennedy, who said Nephron has also developed, in partnership with Lexington Medical Center, a transport medium for nasal swabs used in the testing process.

    Nephron has hired its own nurse practitioner and installed a chief medical officer, Kennedy said. She said the department-by-department testing of employees will continue through this week.

    “The more we test, we’re going to find people that are asymptomatic, but it’s important for us to get this contact tracing thing figured out, get a baseline, get people home and get them well,” she said.

  • sam patrick posted an article
    Nephron announces new partnership see more

    Nephron Pharmaceuticals Corporation, one of the fastest growing pharmaceutical companies in the country, announced a new partnership with One Medical, a leading national digital health and primary care organization that combines 24/7 access to virtual care and digital health tools with COVID-19 testing services to businesses and employees.

    “Re-opening businesses, and getting our economy moving again, is one of our highest priorities,” said Nephron CEO Lou Kennedy, who is a member of Governor Henry McMaster’s #accelerateSC, the coordinated COVID-19 advisory team tasked with recommending economic revitalization plans for South Carolina. “Part of the new normal for businesses is testing employees to make sure the workplace is safe. We couldn’t be prouder to offer COVID-19 testing services to our employees and neighbors.”

    Kennedy and John Singerling, Chief Network Officer of One Medical and a longstanding healthcare executive based in South Carolina, are working together to make this partnership a reality, hoping that it serves as an example for businesses around the country.

    The Nephron CLIA-Certified lab has procured state-of-the-art technology for COVID-19 real-time PCR testing and serological antibody testing for its own employees, and for employees of neighboring businesses. The lab intends to integrate with One Medical’s technology platform, which is capable of supporting a comprehensive workplace reentry COVID-19 testing program. One Medical’s virtual care solutions facilitate scheduling for specimen collection and digitally documenting those test results. It also screens and evaluates clinical risk factors and symptoms and supports employer tracking and reporting needs.

    “I am very pleased to be working alongside the Nephron team to leverage One Medical’s digital health platform as a way to help get South Carolinians back to work safely,” said One Medical Chief Network Officer, John Singerling. “Currently working with over 7,000 employers nationwide has allowed One Medical to build a comprehensive workplace reentry program that is grounded in medicine and testing, and powered by our technology, which allows for seamless tracking, tracing and ongoing monitoring.”

    SARS-CoV-2 PCR tests diagnose whether a person is infected with the virus by using technology that analyzes viral genetic material. Antibody tests check blood for antibodies. If present, antibodies indicate a person has been previously or is currently infected by the virus.

     

    Nephron Pharmaceuticals Corporation has been on the frontlines of the nationwide COVID-19 response. The West Columbia-based company develops and produces safe, affordable generic inhalation solutions and suspension products that can be used to treat severe respiratory distress symptoms associated with COVID-19. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. These products are used, many times, to sedate patients and keep them comfortable when health care professionals place them on ventilators in the fight against the virus.

  • sam patrick posted an article
    Nephron gets nod from FDA see more

    West-Columbia headquartered-Nephron Pharmaceutical Corp.’s fight against the COVID-19 pandemic has received an additional weapon.

    The Food and Drug Administration approved the company’s request to add a production line used in the manufacturing of bronchodilator albuterol today, Nephron CEO Lou Kennedy told the Columbia Regional Business Report.

    “This news came in 20 minutes ago,” Kennedy said Monday morning. “People are cheering. It’s like The Price is Right or something.”

    Kennedy said she expects to hear whether a second production line has been approved later this week.

    Last month, Kennedy petitioned the FDA to add up to six production lines moved to Columbia from the company’s previous Florida headquarters in 2019. Kennedy said the additional lines could help the sterile respiratory medication manufacturer keep up with unprecedented demand.

    Kennedy said March saw a 141% increase in the doses of inhalation solutions Nephron typically produces a month.

    “We went from a regular month of about 80 million shipped to 193 million shipped in March. That’s just for the respiratory side,” she said. “For our sterile injectable medications that we make for all the hospitals in America that have drug shortage needs, that was up by like 22%. We’re seeing the same exact trend in April.”

    Kennedy praised the FDA for its quick response, saying the federal agency granted Nephron a CBE-30, “which means Change Being Effected. That’s giving you a goal date of 30 days or less to review your material and be able to say yes or no,” she said.

    “That’s really something. You’ve just got to know and feel good as a patient or a potential patient in America that the FDA has been working with me on the phone almost every day, or by email, trying to get this through expeditiously so that we can crank up a few more lines.

    “As much as we can make, we’re selling. I don’t want to get behind. So if we can get these other lines approved pretty quickly, then we’ll be able to pump out — if I get four lines, at least another 50 million a month.”

    Also helping meet demand, Kennedy said, are the efforts of the S.C. Ports Authority.

    Last Thursday, four gigantic containers of automated packaging equipment arrived at Nephron headquarters from Switzerland. Today, the company is expecting air delivery of critical supplies from Italy, one of the countries hardest-hit by the COVID-19 pandemic.

    “You know how difficult that was to pull off?” Kennedy said.

    Kennedy developed a working relationship with the port as she moved hundreds of millions of dollars in equipment from Florida to West Columbia when Nephron relocated to South Carolina in 2014. During her time as chair of the S.C. Chamber of Commerce from 2018-19, Kennedy came to know S.C. Ports CEO Jim Newsome and COO Barbara Melvin well.

    Expecting last week’s shipment of automated equipment to help Nephron workers quickly label, package and ship products, Kennedy called Melvin.

    “I reached out to see what the situation was going to be like in getting these pieces of equipment,” she said. “That equipment, which was four giant containers, arrived to the dot at 9 a.m. (Thursday) morning all because of two great South Carolina partners — UPS and its hub that’s located one exit from me, and the Ports Authority.

    “All of these drugs that are packaged will go to benefit speedier to-market products for patients with COVID-19. … This is front-line equipment that we need to get our products to market quicker.”

    Nephron is also gearing up to begin releasing 100-mL saline bags for administration of sodium chlorine. The minibags, made scarce after the 2017 hurricane season hit manufacturer Baxter Healthcare hard, are once again in short supply, Kennedy said.

    “We are very happy to say that we’ve been producing 100-mL saline for the last two weeks in anticipation for this going on shortage,” said Kennedy, who said the bags would be released this past Friday.

    While Nephron has ramped up production in response to previous respiratory illnesses such as SARS and H1N1, Kennedy said the COVID-19 crisis is unlike anything she’s ever seen. Nephron began making its own hand sanitizer last month, distributing 50 liters to the William Jennings Bryan Dorn Veteran Affairs Center.

    “I had absolutely no idea we’d reach these levels. I couldn’t even imagine, can’t even imagine, still am trying to process,” Kennedy said. “One particular day, two or three weeks ago, one hospital system in New York ordered 3,000 nebulizers from us. A typical thing might be 50, no more than 100. They ordered 3,000.”

    S.C. Ports and other transportation partners have helped Nephron fill the exploding demand, Kennedy said, while Nephron workers are proud to be playing a role in combating the virus.

    “I couldn’t even begin to compare ourselves with what they’re doing at hospitals, but there is a true sense of patriotism,” she said. “People are coming to work optimistic in the fact that they’re helping, in their own small way, American patients.”

  • sam patrick posted an article
    Monday Moment for 4-6-20 see more

    SCBIO's latest Monday Moment arrives amidst the COVID-19 storm to provide meaningful and inspiring information in 2 minutes or less. This week, enjoy an uplifting reminder from Nephron's Lou Kennedy that we're all in this together, plus helpful webinars, news on how SC is stepping up and the ever-popular 3 Great LinksClick here.

     

  • sam patrick posted an article
    Nephron seeks to stem coronavirus concerns with expanded offerings see more

    In response to the novel coronavirus pandemic, West Columbia-based Nephron Pharmaceuticals Corp. has asked the Food and Drug Administration for permission to add up to six filling lines to ramp up its production of sterile respiratory medication.

    Nephron CEO Lou Kennedy said she spoke with the FDA on Tuesday morning and is “waiting to hear back.” Kennedy also said Nephron will begin making its own hand sanitizer as early as this week.

    Nephron, which CEO Lou Kennedy said is one of two companies in the U.S. that produce 98% of the nebulizer solutions used in hospitals or sold in retail outlets, relocated to South Carolina from Florida in 2014.

    “We didn’t move all the equipment right away,” moving an additional six filling lines to South Carolina in 2019, Kennedy said. She said she had been in discussion with the FDA for permission to bring those machines online. A meeting had been scheduled for March 22 before she made another request Tuesday.

    West Columbia-based Nephron has asked for FDA approval to add up to six filling lines for its respiratory medication manufacturing. CEO Lou Kennedy also announced the company will begin making hand sanitizer this week. (Photo/File)

    The eight filling lines currently being used in production of the inhalation solutions Nephron makes typically produce 80 to 85 million doses a month “on a regular basis” and are capable of making up to 110 million monthly doses, Kennedy said.

     

    “As of yesterday, we had orders on the books for 87 million, so already a month’s worth,” Kennedy said. “For the last two weeks, those orders have been running about 48% higher than we would normally see. … We do have backstock that we’ve built up in inventory, (but) that won’t last forever.”

    To maximize Nephron’s 24-hour, seven-day-a-week production schedule, Kennedy said the company has begun providing in-house child care. Children are provided food, and already stringent cleaning efforts have been “tripled,” Kennedy said. She said the same methods used to maintain sterile facility conditions, including the use of a fogging machine and wiping down surfaces with isopropyl alcohol and hydrogen peroxide, are being deployed in the day care.

    “We’re really good at cleaning here, because we only make sterile drugs,” Kennedy said. “I’m very confident about making a clean environment for these children.”

    During a conference call Tuesday, Kennedy also said Nephron has received FDA approval to begin making its own hand sanitizer and ordered supplies to do so on Monday.

    “We will take care of the Nephron family first, and after we do that, we will look at should we go through churches, the Salvation Army, how can we help the community, and/or commercial production,” she said. “I’ve had at least six requests from various sales reps across the country. Hospitals are asking can we make that hand sanitizer for them.”

    The plan is to produce 50-liter batches of a strong, FDA recipe without fragrances or other diluting agents, Kennedy said. She said she will gift what is left over from the first batch, after Nephron employees and their families have been served, to local charities.  

    Kennedy said as early as December, Nephron began taking stock of things such as the resin used to make vials of its liquid medication as well as its supply of active pharmaceutical ingredients. “We are fortunate that we have more than a year’s supply of that (API) on hand,” she said.

    Nephron makes bronchodilators including albuterol used to treat respiratory illnesses such as bronchial asthma, pneumonia, emphysema and croup. It also manufactures Pocket Nebs, which are portable, battery-charged nebulizers.

    Novel coronavirus can cause cough, shortness of breath and breathing difficulties. Severe infections can lead to complications including pneumonia, according to the World Health Organization.

    Increased product demand during cold, cough and allergy season, as well as past experience with respiratory illnesses including SARS and H1N1, have made the company ever-vigilant, Kennedy said.

    “We make sure to be very rock-solid in our preparation to accommodate the needs of America,” she said.

    Kennedy said hiring and training has already begun in anticipation of FDA approval of the additional filling lines.

    “We have the people to be able to ramp that up right now,” she said. “ … If we don’t get our hands wrapped around this quickly, meaning we squelch the spread, get control of the spread, it’s going to be a long, hard road. But it’s easily solved if the FDA allows me to ramp up the five or six other lines that I brought here from Florida.”

  • sam patrick posted an article
    Subject matter leaders from across Palmetto State to cover what businesses need to know see more

    March 9, 2020 – SCBIO will host a full day program March 17 -- Life Sciences Boot Camp: Insights on SC’s Fastest-Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.

    To be held at the SC Hospital Association’s Yates Conference Center in Columbia, the program will run from 8:30 a.m. until 1 p.m. and will feature a light breakfast followed by presentations from over 15 noted life sciences industry leaders.  Confirmed topics and speakers include:

    • Best Practices in Life Sciences Recruiting & Retention – addressing how the state’s life sciences leaders are attracting, training and retaining top talent will be Lou Kennedy, CEO of Nephron Pharmaceuticals; Shawn Regan, CEO of Rhythmlink; Andrew Lee, Founder of IMCS, and Matt Vaadi, CEO of ERG
    • Partnering Effectively with Higher Education & Research Universities – ways to tap into the wealth of resources, knowledge and experience prevalent in the state’s higher education and research universities will be explained by a panel comprised of Anthony Herrera, Executive Director of Furman University Entrepreneurship & Innovation; Angela Lockman, Director of Partnerships and Strategic Initiatives for Clemson University; Chad Hardaway, Assoc. Director of the University of South Carolina Office of Economic Engagement; Carol Moore, President of Columbia College; and Michael Rusnak, Executive Director, MUSC Foundation for Research Development
    • Accessing Capital to Grow Your Life Sciences Organization – the secrets to finding capital to grow and expand your organization, from start-up to growth company, will be unveiled by John Osborne, Principal with Good Growth Capital; Jill Sorensen, Executive Director of SC Launch; and Tyler Tatum of 3Phase SC
    •  Attracting & Retaining Life Sciences Organizations – three economic development experts will share how the Palmetto State is going about growing the life sciences industry here, and what plans are to make it even more attractive tomorrow.  Speaking will be Stephanie Few, Partner with Womble Bond Dickinson; Jeremy Migliara, Shareholder with Elliott Davis; and Will Clarke, Manager with Elliott Davis
    • Protecting Your Life Sciences Organization from Cybercrime – will be addressed by cybersecurity expert Delano Collins, Vice President of Cybersecurity with Corsica Technologies.  He’ll address how planning defense in depth -- from network and systems security to industry compliance and employee training -- can set organizations up for security and success.

    SCBIO Investor Organizations receive one registration at no charge, and additional attendees from Investor organizations as well as SCBIO registered Members pay only $50 for the program.  The general public and Non-Members can attend for just $100.  Fees include the full program, plus a light breakfast and lunch. To register or for more details, visit the Events page at www.SCBIO.org/.  Interested students and media members are invited to attend, with advance registration, at no cost.

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 675 firms directly involved and 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.  Life sciences is recognized as the fastest-growing segment of South Carolina’s knowledge economy.

  • sam patrick posted an article
    Nephron's Lou Kennedy appointed by Governbor to SCRA Executive Committee see more

    SCRA, a public, nonprofit corporation chartered to grow South Carolina’s innovation economy and foster job creation, announced the appointment by Gov. Henry McMaster of Lou Kennedy to the SCRA Board of Trustees’ Executive Committee.

    The nine-member group is comprised of the presidents of Clemson University, the Medical University of South Carolina and the University of South Carolina, the governor or designee (to serve as Chairman), an additional appointee of the governor, the chairman of the House Ways and Means Committee or designee, the chairman of the Senate Finance Committee or designee and two additional members.

    Ms. Kennedy is the president, CEO and owner of Nephron Pharmaceuticals Corporation, a woman-owned business that leads the world in the manufacturing of generic respiratory medications. Kennedy received her Bachelor of Arts in Public Relations from the University of South Carolina. She has received numerous awards in South Carolina and across the country for her achievements in business and leadership. Kennedy is also the immediate past chairman of the S.C. Chamber of Commerce and chairman of the Board of Directors of SCBIO, the state's official life sciences organization.

    “I am excited to welcome Ms. Kennedy to SCRA’s Executive Committee,” said Don Herriott, chairman of the SCRA Board. “Her extensive business and leadership experience has had a tremendous positive impact on South Carolina and makes her a valuable addition to the governing body of SCRA.”

  • sam patrick posted an article
    Nephron partnership helps patients receive anesthetics faster see more

    A new partnership between Nephron Pharmaceuticals Corp. and National Medical Products Inc. will help provide more patients with a quick and simple delivery of anesthetic medications, according to a news release from Nephron.

    National Medical Products is the developer of the single-use, subcutaneous J-Tip Needle-Free Injector. Hospitals which use the injector will now be able to use Nephron-developed technology in a Luer lock syringe, buffered and pre-filled with lidocaine, to fill it.

    “This new partnership is a huge win for patients, and we are extraordinarily excited to announce it,” Lou Kennedy, CEO of West Columbia-headquartered Nephron, said in the release. “Working together with the developers of J-Tip, we are making sure that the delivery of anesthetic medications is safe, easy-to-use and virtually pain-free, because patients deserve nothing less.”

    California-based National Medical Products, established in 2001, refined a jet-injection technology previously used by the military for vaccine delivery to create a self-contained injector that uses compressed carbon dioxide to provide an anesthetic effect in one to two minutes, according to the release. The injector is most commonly used before procedures such as IV insertions and blood draws.

    Nephron said the companies hope the partnership will help reach more patients.

  • sam patrick posted an article
    SC Commerce's Bobby Hitt, Abbott's Tom Strange, Nephron saluted by SCBIO see more

    Nearly 350 industry leaders on hand to salute inaugural honorees for commitment to advancing South Carolina’s booming life sciences industry

     

     NOVEMBER 2, 2018 – To resounding applause from a record gathering from 4 countries, 22 states and virtually every county in South Carolina, life sciences leaders saluted three leaders – two individuals and one organization – for profound positive impact and exceptional contributions to the advancement of South Carolina’s $11.4 billion life sciences industry.

     South Carolina Secretary of Commerce Robert M. “Bobby” Hitt III was presented with the inaugural South Carolina Life Sciences Hall of Fame Award for his personal championing of the life sciences industry, which today has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.  SC Commerce is a Founding Partner and strategic supporter of SCBIO, and has been highly instrumental in helping the rapid growth of life sciences in the Palmetto State.

     Mr. Hitt has served as South Carolina Secretary of Commerce since January 2011. Promoting a team-first approach to economic development, Hitt has positioned the S.C. Department of Commerce and its many partners and allies for industry recruitment success. Since 2011, Team South Carolina has recruited more than $35 billion in capital investment and approximately 125,000 new jobs to the state. This year alone, multiple world-class companies have made significant investments in South Carolina, including BMW, Samsung and Volvo Cars.  Before his time as Secretary of Commerce, Hitt served as manager of Corporate Affairs at the BMW Manufacturing Company in Spartanburg County after 17 years as managing editor of The State and Columbia Record newspapers.

     Presented with the inaugural South Carolina Life Sciences Pinnacle Award for Individual Contribution to the industry was Tom Strange, Senior Director of Research & Development for Abbott Labs in Liberty, South Carolina.  With an extensive background in materials science, Mr. Strange holds 48 patents and has authored numerous papers covering all aspects of capacitor development. He began his illustrious career with Philips Components in 1979 leading research activity involving development of capacitors that made thoracic implantable cardioverter defibrillators possible. Today, with over 20 years at St Jude Medical/Abbott, his team continues to define state of the art in implantable medical devices for pacing and arrhythmia correction, neuromodulation and battery performance. 

    Honored for his exceptional industry-related contributions and profound impact on the state, its citizens and the life sciences industry, Mr. Strange led efforts to establish SC Launch!, the public/private initiative with the SC legislature to fund start-up activities in SC under SCRA, and helped to launch SCBIO as an affiliate of the national BIO organization. He holds numerous honors and awards, and earned undergraduate and graduate degrees in Physics from the University of South Carolina.

    Presented with the inaugural South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry was Nephron Pharmaceuticals of West Columbia, represented by owners Lou and Bill Kennedy.  A Vision Partner of SCBIO, CEO Lou Kennedy joined Nephron Pharmaceuticals in 2001, and was named President/CEO in 2007. She led the creation of a state of the art manufacturing facility in West Columbia in 2014, and oversaw development of a national sales force which helped Nephron grow by 300% and increased shipped product to over one billion doses annually. 

    Honored for Nephron’s economic, innovation, social and quality of life impact in the state, the Kennedy’s helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy. Ms. Kennedy serves on or chairs numerous boards including those of SCBIO, the SC Chamber of Commerce, the National Bank of South Carolina, and the South Carolina Manufacturers Alliance.

    The three honorees joined BIO global CEO Jim Greenwood and more than 50 additional national speakers at SCBIO 2018 – the annual conference which brought top leaders and executives from life sciences organizations across the state and nation to Charleston, South Carolina October 23-25.

    Included among attendees were scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America including DePuy Synthes Global Orthopedic Leader I.V. Hall, J.P. Morgan Executive Director of Healthcare Investment Banking Bell Zhong, MUSC President David Cole, USC President Harris Pastides, Siemens Healthineers North Americas President Dave Pacitti, and numerous others.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    “The life sciences industry is a major driver of South Carolina’s economy, and these noted honorees and this conference is testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “We’re pleased to honor them for their many contributions, and salute them for the advances they have facilitated for this industry.”

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    For additional information on SCBIO, visit www.SCBIO.org.

  • sam patrick posted an article
    USC, Nephron partner to improve safety through automation see more

    Nephron Pharmaceuticals Corporation has joined forces with the University of South Carolina's College of Engineering and Computing and the College of Pharmacy to design and implement an automation process that significantly boosts production of pre-filled medication, reducing the physical burden on workers and increasing patient safety.

    Traditionally, pre-filled syringes are filled by hand in clean-room environments. In recent years, federal regulations governing sterile compounding have become more stringent and complex as a result of accidental contaminations.  The use of robots to compound prescription products exceeds those new federal guidelines and provides a more sterile environment with better accuracy and precision than traditional methods of compounding. 

    The research collaboration with Nephron will position UofSC to develop state-of-the-art sterile compounding methods benefiting hospitals throughout South Carolina and the nation.

    “Demand for pre-filled medication has exploded in recent years, and our company is responding to the market needs for affordable and accessible life-saving medications in pre-filled syringes,” said Nephron CEO Lou Kennedy. “We are excited to partner with innovative students and leading researchers from Engineering and Pharmacy at the University of South Carolina to meet the demands of hospitals and patients, and we look forward to working together for years to come.”

    To help Nephron meet the market demand, the College of Engineering and Computing and the College of Pharmacy have finalized plans to build a fully functional sterile compounding lab at the McNAIR Aerospace Center. This fully functional, first-of-its-kind compounding suite will offer students the opportunity to learn and develop the techniques of sterile, robotic manufacturing processes for human drug compounding. 

    Between the College of Engineering and Computing and the College of Pharmacy, well over a dozen undergraduate, graduate and doctoral students are involved in the project. Utilizing a state-of-the-art robot from UofSC corporate partner Yaskawa Motoman Robotics, as well as Process Simulate — a Siemens software package included in its $628 million gift to McNAIR Center and to the College of Engineering and Computing in 2017 — these students are learning skills that will immediately translate to increased job opportunities upon graduation.

    “This team is a unique collection of talents, not just from engineering but with advisers from the College of Pharmacy and partners from Office of Economic Engagement as well,” said Ramy Harik of the McNAIR Aerospace Center, who leads the project design team. “By bringing together a cross-disciplinary team, and constantly seeking feedback from Nephron engineers and pharmacists, our students are building a real-life application that, when completed, will be implemented in production. Particularly for our undergraduate students, this type of impactful research experience is invaluable.”

    The Nephron project is a continuation of an ongoing university partnership with the company. When Nephron Pharmaceuticals Corp. opened its manufacturing campus in West Columbia in 2015, proximity to the flagship research university was an important factor. Owned and operated by UofSC alumni Lou (’84) and Bill (’66) Kennedy, whose $30 million endowment created The Kennedy Pharmacy Innovation Center (KPIC) in the College of Pharmacy in 2010, Nephron has found success by meeting the increasing demand for pre-filled medications at medical facilities nationwide.

    “Our engagement with industry leaders like Nephron is key to helping our students gain important knowledge and experience while solving real-world problems,” said UofSC President Bob Caslen. “By tapping into our research expertise, our corporate partners can bring innovative products to market, which grows their businesses and the state’s economy. That ensures more opportunity for all South Carolinians and furthers our university system’s mission of service.”

    Nephron is a certified woman-owned business and one of the fastest-growing pharmaceutical companies in the country.  In 2017, they added a $12.5 million, 36,000-square-foot expansion to its manufacturing facility so they would be strategic in meeting the U.S. drug shortages. By partnering with UofSC students and researchers, Nephron seeks to fully automate parts of the syringe-filling process.

  • sam patrick posted an article
    Nephron, Clemson partner to meet hospital needs see more

    Nephron Pharmaceuticals Corporation is partnering with Clemson University to create a robotic solution for syringe-filling automation to enhance sterile manufacturing in the pharmaceutical production process and keep up with growing hospital demands.

    “We are excited about our new partnership with Clemson and we cannot wait to get started,” said Nephron CEO Lou Kennedy. “Working together with Clemson’s world-class researchers and engineers we can ensure that the pharmaceutical manufacturing process remains safe and we can deliver life-saving drugs to patients and hospitals across the country.”

    The university’s newest strategic partner is turning to Clemson to harness the power of technology for more efficient processes. To do so, Nephron is enlisting the expertise of the College of Engineering, Computing and Applied Sciences professor and researcher Yue “Sophie” Wang and mechanical engineering doctoral student Brandon Delspina and mechanical engineering master’s student Yu “Gloria” Zhang.

    Their robotics research for syringe automation will support the Nephron 503B Outsourcing Facility, a cGMP manufacturer providing sterile, pre-filled medications to address persistent drug shortages in hospitals and medical facilities across America.

    Based in West Columbia, Nephron is a certified woman-owned business and one of the fastest-growing companies in South Carolina. This is Nephron’s first partnership with the university and was developed through External Affairs’ Office of Corporate Partnerships and Strategic Initiatives at Clemson University.

    “When the External Affairs’ Office of Corporate Partnerships and Strategic Initiatives approached us about this project we were excited to get involved,” said Wang, associate professor of mechanical engineering. “Our work in robotics can have a tremendous impact on individuals across the country and we are looking forward to working on this because of its benefits for the many patients Nephron serves.”

    “Industry needs are changing at a rapid rate and Clemson is equipped to support companies like Nephron. Together, we have created a mutually beneficial project to enhance their capabilities while providing the university’s students with unique, hands-on research experience,” said Angie Leidinger, vice president for External Affairs. “This partnership is a testament to the work happening at Clemson and we’re looking forward to this collaboration, which will advance their business and benefit South Carolinians.”